Dimension Therapeutics
http://dimensiontx.com/index.php
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Dimension Therapeutics
Finance Watch: Exo Raises $78m To Advance Exosite-Targeting Small Molecules
Also, Atlas Venture and Advent France Biotechnology raise new venture capital funds, Corium secures $235m in debt to commercialize ADHD drug and CBMG leads recent VC financings with $120m series A round.
Interview: Silence Therapeutics’ Chair On Why Keeping Quiet Has Done The Biotech No Favors
Silence Therapeutics’ executive chair, Annalisa Jenkins, talks to Scrip about why there’s more to the company than a court case.
Biopharma Quarterly Dealmaking Statistics, Q3 2017
Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.
Asia Executives To Watch: Alcon Japan New President, AZ International EVP
Autumn has brought a flurry of personnel changes with Kyowa FujiFilm getting a new president and AZ a new executive vice president for the international region. Fosun and the medtech firm, Median Technologies, have also seen personnel movement.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice